Eyelid Malignancies

  • Preamjit Saonanon


Malignant tumors of the eyelids represent approximately 5–10% of all skin malignancies. The most frequent lesion worldwide is basal cell carcinoma (85–90%), followed by squamous cell carcinoma in Caucasians, whereas sebaceous carcinoma is the second most common eyelid malignant lesion in Asians. Aging changes and epithelial damage from excessive exposure to UV light are predisposing factors, particularly in light-skinned individuals. Typical clinical signs that are suggestive of malignancy include slow, painless growth with destruction of normal eyelid architecture and madarosis. However, malignant neoplasms can also present with rapid growth, pain, or other variable symptoms and signs. An incisional or excisional biopsy is essential to confirm all clinically suspicious lesions. Surgical complete excision with histologic examination of the margins is the gold standard of treatment. Adjuvant therapies such as radiation, chemotherapy, and targeted therapies will be discussed briefly in this chapter.


Eyelid malignancy Eyelid cancer Basal cell carcinoma Squamous cell Sebaceous cell Sebaceous carcinoma Melanoma eyelid Merkel cell 


  1. 1.
    Cook BE Jr, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology. 1999;106:746–50.CrossRefGoogle Scholar
  2. 2.
    Deprez M, Uffer S. Clinicopathological features of eyelid skin tumors: a retrospective study of 5504 cases and review of literature. Am J Dermatopathol. 2009;3:256–62.Google Scholar
  3. 3.
    Watanabe A, Sun MT, Pirbhai A, et al. Sebaceous carcinoma in Japanese patients: clinical presentation, staging and outcomes. Br J Ophthalmol. 2013;97:1459–63.CrossRefGoogle Scholar
  4. 4.
    Margo CE, Waltz K. Basal cell carcinoma of the eyelid and periocular skin. Surv Ophthalmol. 1993;38:169–92.CrossRefGoogle Scholar
  5. 5.
    Honavar SG, Shields JA, Shields CL, et al. Basal cell carcinoma of the eyelids associated with Gorlin-Gorltz syndrome. Ophthalmology. 2001;108:1115–23.CrossRefGoogle Scholar
  6. 6.
    Malhotra R, Huilgol SC, Huynh NT, et al. The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up. Ophthalmology. 2004;111:631–6.CrossRefGoogle Scholar
  7. 7.
    Silverman N, Shinder R. What’s new in eyelid tumors. Asia Pac J Ophthalmol. 2017;6:143–52.Google Scholar
  8. 8.
    de Macedo EM, Carneiro RC, de Lima PP, et al. Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial. BMC Ophthalmol. 2015;15:35.CrossRefGoogle Scholar
  9. 9.
    Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–9.CrossRefGoogle Scholar
  10. 10.
    Faustina M, Diba R, Ahmadi MA, et al. Patterns of regional and distant metastasis in patients with eyelid and periocular squamous cell carcinoma. Ophthalmology. 2004;111:1930–2.CrossRefGoogle Scholar
  11. 11.
    Donaldson MJ, Sullivan TJ, Whitehead KJ, et al. Squamous cell carcinoma of the eyelids. Br J Ophthalmol. 2002;86:1161–5.CrossRefGoogle Scholar
  12. 12.
    Ford J, Thakar S, Thuro B, et al. Prognostic value of the staging system for eyelid tumors in the 7th edition of the American Joint Committee on Cancer Staging manual. Ophthal Plast Reconstr Surg. 2017;33:317–24.CrossRefGoogle Scholar
  13. 13.
    Esmaeli B, Nasser QJ, Cruz H, et al. American Joint Committee on Cancer T category for eyelid sebaceous carcinoma correlates with nodal metastasis and survival. Ophthalmology. 2012;119:1078–82.CrossRefGoogle Scholar
  14. 14.
    Yin VT, Warneke CL, Merritt HA, et al. Number of excisions required to obtain clear surgical margins and prognostic value of AJCC T category for patients with eyelid melanoma. Br J Ophthalmol. 2014;98:1681–5.CrossRefGoogle Scholar
  15. 15.
    Esmaeli B, Youssef A, Naderi A, et al. Collaborative Eyelid Skin Melanoma Group. Margins of excision for cutaneous melanoma of the eyelid skin: the Collaborative Eyelid Skin Melanoma Group Report. Ophthal Plast Reconstr Surg. 2003;19:96–101.CrossRefGoogle Scholar
  16. 16.
    Missotten GS, de Wolff-Rouendaal D, de Keizer RJ. Merkel cell carcinoma of the eyelid review of the literature and report of patients with Merkel cell carcinoma showing spontaneous regression. Ophthalmology. 2008;115:195–201.CrossRefGoogle Scholar
  17. 17.
    Herbert HM, Sun MT, Selva D, et al. Merkel cell carcinoma of the eyelid: management and prognosis. JAMA Ophthalmol. 2014;132:197–204.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Preamjit Saonanon
    • 1
    • 2
  1. 1.Department of Ophthalmology, Faculty of MedicineChulalongkorn UniversityBangkokThailand
  2. 2.Department of OphthalmologyKing Chulalongkorn Memorial Hospital, Thai Red Cross SocietyBangkokThailand

Personalised recommendations